JY BioMed is developing a gamma delta (γδ) T cell platform focused on leveraging the innate cytotoxic potential of these unique immune cells. Unlike conventional alpha beta T cells, gamma delta T cells recognize stress-induced ligands independently of antigen presentation through MHC molecules, enabling rapid and broad tumor targeting. Our platform includes the expansion of highly pure Vδ2+ and Vδ1+ gamma delta T cells, optimized for large-scale production and clinical translation. This approach may offer advantages in treating solid tumors, hematologic malignancies, and immune dysregulation without the need for prior antigen sensitization.

​

Current research programs span indications such as glioblastoma, pancreatic cancer, relapsed AML, liver cancer, lung cancer, and metastatic triple negative breast cancer. All development activities remain under preclinical investigation, guided by global standards for cell-based therapeutic innovation.